Advertisement

Epidemiological Studies of Specified Rare and Intractable Disease

TNF Receptor-Associated Periodic Syndrome (TRAPS)
  • Naoyasu Ueda
  • Takahiko HoriuchiEmail author
Chapter
Part of the Current Topics in Environmental Health and Preventive Medicine book series (CTEHPM)

Abstract

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a representative of autoinflammatory diseases. We conducted a nationwide survey for patients with TNFRSF1A variants in Japan. We obtained clinical and genetic features of 51 patients from 33 independent families. The most common variant was T61I (appearing in 49% of patients), and it was identified in 7 of 363 healthy controls. The common clinical features of Japanese patients were fever of >38 °C (100% of patients), arthralgia (59%), and rash (55%). The prevalence of abdominal pain (36%), myalgia (43%), and amyloidosis (0%) was significantly lower in Japanese patients than in Caucasian patients. Patients with TNFRSF1A variants are very rare in Japan, as in other countries, but there are a number of clinical and genetic differences between Japanese and Caucasian patients.

Keywords

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) TNFRSF1A Japan Japanese T61I 

References

  1. 1.
    Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, Mcdermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS). Medicine. 2002;81:349–68.  https://doi.org/10.1097/00005792-200209000-00002.CrossRefPubMedGoogle Scholar
  2. 2.
    Ueda N, Ida H, Washio M, Miyahara H, Tokunaga S, Tanaka F, et al. Clinical and genetic features of patients with TNFRSF1A variants in Japan: findings of a Nationwide survey. Arthritis & Rheumatology. 2016;68:2760–71.  https://doi.org/10.1002/art.39793.CrossRefGoogle Scholar
  3. 3.
    Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror Autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621–68.  https://doi.org/10.1146/annurev.immunol.25.022106.141627.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mulley J, Saar K, Hewitt G, Rüschendorf F, Phillips H, Colley A, et al. Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet. 1998;62:884–9.  https://doi.org/10.1086/301793.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Mcdermott MF, Ogunkolade BW, Mcdermott EM, Jones LC, Wan Y, Quane KA, et al. Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet. 1998;62:1446–51.  https://doi.org/10.1086/301886.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mcdermott MF, Aksentijevich I, Galon J, Mcdermott EM, Ogunkolade B, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133–44.  https://doi.org/10.1016/s0092-8674(00)80721-7.CrossRefPubMedGoogle Scholar
  7. 7.
    Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 1993;73:431–45.  https://doi.org/10.2210/pdb1tnr/pdb. CrossRefPubMedGoogle Scholar
  8. 8.
    Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351–4.  https://doi.org/10.1126/science.288.5475.2351.CrossRefPubMedGoogle Scholar
  9. 9.
    Hawari FI, Rouhani FN, Cui X, Yu Z-X, Buckley C, Kaler M, et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci. 2004;101:1297–302.  https://doi.org/10.1073/pnas.0307981100.CrossRefPubMedGoogle Scholar
  10. 10.
    Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood. 2006;108:1320–7.  https://doi.org/10.1182/blood-2005-11-006783.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci. 2010;107:9801–6.  https://doi.org/10.1073/pnas.0914118107.CrossRefPubMedGoogle Scholar
  12. 12.
    Bachetti T, Chiesa S, Castagnola P, Bani D, Zanni ED, Omenetti A, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis. 2012;72:1044–52.  https://doi.org/10.1136/annrheumdis-2012-201952.CrossRefPubMedGoogle Scholar
  13. 13.
    Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med. 2011;208:519–33.  https://doi.org/10.1084/jem.20102049.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J, et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis. 2012;71:2035–43.  https://doi.org/10.1136/annrheumdis-2011-201197.CrossRefPubMedGoogle Scholar
  15. 15.
    Ravet N, Rouaghe S, Dode C, Bienvenu J, Stirnemann J, Levy P, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis. 2006;65:1158–62.  https://doi.org/10.1136/ard.2005.048611.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tchernitchko D, Chiminqgi M, Galactéros F, Préhu C, Segbena Y, Coulibaly H, et al. Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan west African populations. Eur J Hum Genet. 2004;13:513–5.  https://doi.org/10.1038/sj.ejhg.5201344.CrossRefGoogle Scholar
  17. 17.
    Dosualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factor–induced apoptosis: Pathogenetic and clinical implications. Arthritis Rheum. 2006;54:998–1008.  https://doi.org/10.1002/art.21657.CrossRefGoogle Scholar
  18. 18.
    Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001;69:301–14.  https://doi.org/10.1086/321976.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Dieude P, Goossens M, Cornelis F, Michou L, Bardin T, Tchernitchko DO. The TNFRSF1A R92Q mutation is frequent in rheumatoid arthritis but shows no evidence for association or linkage with the disease. Ann Rheum Dis. 2007;66:1113–5.  https://doi.org/10.1136/ard.2006.060764.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Amoura Z, Dodé C, Hue S, Caillat-Zucman S, Bahram S, Delpech M, et al. Association of the R92QTNFRSF1Amutation and extracranial deep vein thrombosis in patients with Behçets disease. Arthritis Rheum. 2005;52:608–11.  https://doi.org/10.1002/art.20873.CrossRefPubMedGoogle Scholar
  21. 21.
    Poirier O, Nicaud V, Gariépy J, Courbon D, Elbaz A, Morrison C, et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness – the ECTIM, AXA, EVA and GENIC studies. Eur J Hum Genet. 2003;12:213–9.  https://doi.org/10.1038/sj.ejhg.5201143.CrossRefGoogle Scholar
  22. 22.
    Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol. 2012;101:525–31.  https://doi.org/10.1007/s00392-012-0422-8.CrossRefPubMedGoogle Scholar
  23. 23.
    Jager PLD, Jia X, Wang J, Bakker PIWD, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41:776–82.  https://doi.org/10.1038/ng.401.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2013;73:2160–7.  https://doi.org/10.1136/annrheumdis-2013-204184.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kallinich T. "periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Ann Rheum Dis. 2005;65:958–60.  https://doi.org/10.1136/ard.2005.043570.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum. 2003;48:2632–44.  https://doi.org/10.1002/art.11215.CrossRefPubMedGoogle Scholar
  27. 27.
    Kusuhara K, Hoshina T, Saito M, Ishimura M, Inoue H, Horiuchi T, et al. Successful treatment of a patient with tumor necrosis factor receptor-associated periodic syndrome using a half-dose of etanercept. Pediatr Int. 2012;54:552–5.  https://doi.org/10.1111/j.1442-200x.2011.03525.x.CrossRefPubMedGoogle Scholar
  28. 28.
    ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74:1636–44.  https://doi.org/10.1136/annrheumdis-2015-207546.CrossRefPubMedGoogle Scholar
  29. 29.
    Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2016;76:173–8.  https://doi.org/10.1136/annrheumdis-2015-209031.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 2012;64:908–13.  https://doi.org/10.1002/art.33416.CrossRefPubMedGoogle Scholar
  31. 31.
    Jacobelli S, Andre M, Alexandra J-F, Dode C, Papo T. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology. 2007;46:1211–2.  https://doi.org/10.1093/rheumatology/kel298.CrossRefPubMedGoogle Scholar
  32. 32.
    Drewe E, Powell R, Mcdermott E. Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology. 2007;46:1865–6.  https://doi.org/10.1093/rheumatology/kem231.CrossRefPubMedGoogle Scholar
  33. 33.
    Siebert S, Amos N, Lawson TM. Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology. 2007;47:228–9.  https://doi.org/10.1093/rheumatology/kem243.CrossRefPubMedGoogle Scholar
  34. 34.
    Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K, et al. Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology. 2009;48:987–91.  https://doi.org/10.1093/rheumatology/kep140.CrossRefPubMedGoogle Scholar
  35. 35.
    Kusuhara K, Nomura A, Nakao F, Hara T. Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr. 2004;163:30–2.  https://doi.org/10.1007/s00431-003-1338-0.CrossRefPubMedGoogle Scholar
  36. 36.
    Washio M, Nakano T, Kawaguchi Y, Takagi K, Kiyohara C, Tsukamoto H, et al. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in Japan: a review of the literature. Mod Rheumatol. 2013;23:210–7.  https://doi.org/10.3109/s10165-012-0737-3.CrossRefPubMedGoogle Scholar
  37. 37.
    Tsuchiya-Suzuki A, Yazaki M, Nakamura A, Yamazaki K, Agematsu K, Matsuda M, et al. Clinical and genetic features of familial Mediterranean fever in Japan. J Rheumatol. 2009;36:1671–6.  https://doi.org/10.3899/jrheum.081278.CrossRefPubMedGoogle Scholar
  38. 38.
    Migita K, Uehara R, Nakamura Y, Yasunami M, Tsuchiya-Suzuki A, Yazaki M, et al. Familial Mediterranean fever in Japan. Medicine (Baltimore). 2012;91:337–43.  https://doi.org/10.1097/MD.0b013e318277cf75.CrossRefGoogle Scholar
  39. 39.
    Manki A, Nishikomori R, Nakata-Hizume M, Kunitomi T, Takei S, Urakami T, et al. Tumor necrosis factor receptor-associated periodic syndrome mimicking systemic juvenile idiopathic arthritis. Allergol Int. 2006;55:337–41.  https://doi.org/10.2332/allergolint.55.337.CrossRefPubMedGoogle Scholar
  40. 40.
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial mediterranean fever. Arthritis Rheum. 1997;40:1879–85.  https://doi.org/10.1002/art.1780401023.CrossRefPubMedGoogle Scholar
  41. 41.
    Ida H. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology. 2004;43:1292–9.  https://doi.org/10.1093/rheumatology/keh320.CrossRefPubMedGoogle Scholar
  42. 42.
    Horiuchi T, Tsukamoto H, Mitoma H, Miyagawa H, Tamimoto Y, Yoshizawa S, et al. Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese. Int J Mol Med. 2004.  https://doi.org/10.3892/ijmm.14.5.813.
  43. 43.
    Ohmori S, Hino R, Nakamura M, Tokura Y. Heparin serves as a natural stimulant of the inflammasome and exacerbates the symptoms of tumor necrosis factor receptor-associated periodic syndrome (TRAPS). J Dermatol Sci. 2012;66:82–4.  https://doi.org/10.1016/j.jdermsci.2011.11.006.CrossRefPubMedGoogle Scholar
  44. 44.
    Ohmori S, Hino R, Nakamura M. Inflammatory response to heparinoid and heparin in a patient with tumor necrosis factor receptor-associated periodic syndrome: the second case with a T61I mutation in theTNFRSF1Agene. J Dermatol. 2014;41:1112–3.  https://doi.org/10.1111/1346-8138.12689.CrossRefPubMedGoogle Scholar
  45. 45.
    Takagi K, Kawaguchi Y, Fujikawa S, Otani T, Sugiura T, Hara M. Tumor necrosis factor receptor-associated periodic syndrome with a C30R mutation in a Japanese family. Mod Rheumatol. 2007;17:265–6.  https://doi.org/10.1007/s10165-007-0580-0.CrossRefPubMedGoogle Scholar
  46. 46.
    Kai M, Tamaki S, Nishikomori R, Takaoka Y, Ohara O, Oshima K. A case of TNF receptor-associated periodic syndrome. Ryumachika (Rheumatology). 2011;45:456–460. In Japanese.Google Scholar
  47. 47.
    Nakamura M. Tokura Y. A novel missense mutation in tumour necrosis factor receptor superfamily 1A (TNFRSF1A) gene found in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with high serum interleukin (IL)-22. Eur J Dermatol. 2010;20:508–9.  https://doi.org/10.1684/ejd.2010.0951. CrossRefPubMedGoogle Scholar
  48. 48.
    Nakamura M, Kobayashi M, Tokura Y. A novel missense mutation in tumour necrosis factor receptor superfamily 1A (TNFRSF1A) gene found in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) manifesting adult-onset still disease-like skin eruptions: report of a case and review of the Japanese patients. Br J Dermatol. 2009;161:968–70.  https://doi.org/10.1111/j.1365-2133.2009.09409.x.CrossRefPubMedGoogle Scholar
  49. 49.
    Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet. 2012;91:713–20.  https://doi.org/10.1016/j.ajhg.2012.08.006.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Romberg N, Moussawi KA, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46:1135–9.  https://doi.org/10.1038/ng.3066.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Canna SW, Jesus AAD, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46:1140–6.  https://doi.org/10.1038/ng.3089.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K. An inherited mutation inNLRC4causes autoinflammation in human and mice. J Exp Med. 2014;211:2385–96.  https://doi.org/10.1084/jem.20141091.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci. 2011;108:14914–9.  https://doi.org/10.1073/pnas.1106015108.CrossRefPubMedGoogle Scholar
  54. 54.
    Gattorno M, Sormani MP, Dosualdo A, Pelagatti MA, Caroli F, Federici S, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum. 2008;58:1823–32.  https://doi.org/10.1002/art.23474.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineMiyazaki Prefectural Miyazaki HospitalMiyazakiJapan
  2. 2.Department of Internal MedicineKyushu University Beppu HospitalBeppuJapan

Personalised recommendations